WHO ICTRP trial
Causes and prevention of thrombosis developed due to the kidney disease…
EUCTR2019-001212-29-DK · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2019-001212-29-DK |
|---|---|
| Public title | Causes and prevention of thrombosis developed due to the kidney disease nephrotic syndrome |
| Scientific title | Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome |
| Primary sponsor | Aarhus University Hospital, Henrik Birn |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Denmark |
| Conditions | Nephrotic syndrome is defined as severe proteinuria (> 0.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of a large number of plasma proteins… |
| Interventions | Trade Name: Fragmin Pharmaceutical Form: Injection INN or Proposed INN: Dalteparin Other descriptive name: Dalteparin Concentration unit: IU international unit(s) Concentration type: up to Concentration number: 18000 - Trade Name: Eliquis… |
| Registration date | Sep 6, 2020 |
| Target size | 70 |
| Secondary IDs | Prot-0824-2019 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: